GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
16 mars 2023 08h45 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new...
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
14 mars 2023 16h16 HE
|
GeneDx Holdings Corp.
Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million Completed financing in January 2023...
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
01 mars 2023 07h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company...
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
28 févr. 2023 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced its contributions to...
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
21 févr. 2023 16h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases
16 févr. 2023 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Feb. 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, continues to...
GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering
31 janv. 2023 16h15 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 31, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A...
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
30 janv. 2023 08h30 HE
|
GeneDx Holdings Corp.
Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype...
GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering
27 janv. 2023 06h00 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 27, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at...
GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering
26 janv. 2023 16h53 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 26, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it...